Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
There is evidence that the use of dipeptidyl peptidase-4 inhibitors (DPP-4) (gliptins) and/or glucagon-like peptide-1 (GLP-1) mimetics is associated with a higher rate of Parkinson's disease compared with the use of other oral antidiabetic drugs 2
The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease
The goal of treatment is not to continually increase the dose but to find your personal sweet spot, the dose where you feel your best and achieve steady, sustainable results
Thorgeirsson, S
doi: 10.1038/nrn960 187 LamN.LeeY.FarberD
US$ 25.85
US$ 22.21
US$ 21.10
US$ 28.45
US$ 21.96
US$ 26.23
